UnitedHealth Group's valuation is under scrutiny. This follows its second-quarter 2026 earnings beat and an active share repurchase program.
The company recorded a 1-year total shareholder return of 53.71%. Some market perspectives suggest the stock may be overvalued. One narrative places its fair value at $395. This figure is below its last close of $420.74.
Opinions on valuation differ based on the market's view of its Optum division versus the core insurance business. The core insurance business focuses on improving margins.
Despite strong performance and a raised full-year outlook, the market shows caution. This relates to earnings quality and potential regulatory risks.
Investment firm Unisphere Establishment increased its stake in the company by 14.3% during the first quarter.